An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Janssen Biotech, Inc.
Study ID
NCT01833039
Status
Approved For Marketing

Conditions

  • Relapsed or Refractory Mantle Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.

Key Dates

Status verified
Jan 2025

Locations (44)

FacilityCityStateZIPSite coordinators
-PhoenixArizona--
-DuarteCalifornia--
-Los AngelesCalifornia--
-StanfordCalifornia--
-DenverColorado--
-NorwalkConnecticut--
-StamfordConnecticut--
-Washington D.C.District of Columbia--
-Miami BeachFlorida--
-OcalaFlorida--
-OrlandoFlorida--
-AtlantaGeorgia--
-ChicagoIllinois--
-SpringfieldIllinois--
-GoshenIndiana--
-Sioux CityIowa--
-LexingtonKentucky--
-LouisvilleKentucky--
-MetairieLouisiana--
-BaltimoreMaryland--
-BostonMassachusetts--
-WorcesterMassachusetts--
-DetroitMichigan--
-RochesterMinnesota--
-Jefferson CityMissouri--
-St LouisMissouri--
-LincolnNebraska--
-OmahaNebraska--
-RenoNevada--
-HackensackNew Jersey--
-New Hyde ParkNew York--
-New YorkNew York--
-SyracuseNew York--
-ClevelandOhio--
-ColumbusOhio--
-HersheyPennsylvania--
-PhiladelphiaPennsylvania--
-WatertownSouth Dakota--
-KnoxvilleTennessee--
-AustinTexas--
-DallasTexas--
-HoustonTexas--
-BurlingtonVermont--
-MorgantownWest Virginia--